Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST101 in advanced solid tumors
NCT04478279Phase 2Active, not recruiting
- Sponsor
- Sapience Therapeutics, Inc.
- Start
- Jul 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of lucicebtide in solid tumor, glioblastoma (GBM), melanoma, breast cancer, prostate cancer (PCa), sponsored by Sapience Therapeutics, Inc.. Started Jul 2020; status: active, not recruiting.
02
Drugs
lucicebtide
03
Conditions
solid tumorglioblastoma (GBM)melanomabreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT04478279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478279.